Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Completed 1

Sponsor Class

NIH 2NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 3

Conditions

Leukemia, Myeloid, Acute 17Precursor Cell Lymphoblastic Leukemia-Lymphoma 15Myelodysplastic Syndromes 15Hematologic Neoplasms 8Leukemia, Myelogenous, Chronic, BCR-ABL Positive 7Lymphoma, Non-Hodgkin 6Neuroblastoma 5Leukemia, Biphenotypic, Acute 5Myeloproliferative Disorders 4Graft vs Host Disease 4Multiple Myeloma 3Medulloblastoma 3Lymphoma, Large B-Cell, Diffuse 3Leukemia 3Hodgkin Disease 3Ganglioneuroblastoma 3Blastic Plasmacytoid Dendritic Cell Neoplasm 3Lymphoma 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Anemia, Refractory, with Excess of Blasts 2Teratoma 1Sarcoma, Myeloid 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Retinoblastoma 1Recurrence 1Pyloric Stenosis, Hypertrophic 1Pinealoma 1Neurofibrosarcoma 1

Interventions

Magnetic Resonance Spectroscopy 7Cyclophosphamide 7dinutuximab 6Topotecan 5Isotretinoin 5Doxorubicin 5Biopsy 5sargramostim 4Vincristine 4Stem Cell Transplantation 4Specimen Handling 4Radiation 4Platinum 4Melphalan 4Colony-Stimulating Factors 4Cisplatin 4Carboplatin 41,2-diaminocyclohexaneplatinum II citrate 4Thiotepa 3Temozolomide 3Irinotecan 3Etoposide 3Congresses as Topic 33-Iodobenzylguanidine 3etoposide phosphate 2Razoxane 2Dexrazoxane 2Busulfan 2lorlatinib 1iberdomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Ganglioneuroblastoma × Thiotepa × 1 year × Clear all
NCT06172296 2026-06-03

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 3 Recruiting
478 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

NCT03786783 2026-06-02

Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma

National Cancer Institute (NCI)

Phase 2 Completed
42 enrolled 12 charts
CNS

Ganglioneuroblastoma

NCT03126916 2026-02-27

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Children's Oncology Group

Phase 3 Recruiting
750 enrolled
CNS

Neuroblastoma, Ganglioneuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡